Becton, Dickinson and Company $BDX Stock Bought by Yousif Capital Management LLC

Yousif Capital Management LLC raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 19.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 69,438 shares of the medical instruments supplier’s stock after acquiring an additional 11,257 shares during the quarter. Yousif Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $12,429,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in BDX. Brown Lisle Cummings Inc. boosted its stake in shares of Becton, Dickinson and Company by 9.2% during the second quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock valued at $97,000 after acquiring an additional 54 shares during the last quarter. Pension & Wealth Management Advisors Inc. raised its stake in Becton, Dickinson and Company by 12.3% in the 3rd quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier’s stock valued at $94,000 after purchasing an additional 56 shares during the last quarter. Elevation Point Wealth Partners LLC raised its stake in Becton, Dickinson and Company by 3.7% in the 2nd quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock valued at $256,000 after purchasing an additional 60 shares during the last quarter. Private Harbour Investment Management & Counsel LLC lifted its holdings in Becton, Dickinson and Company by 1.1% in the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier’s stock valued at $834,000 after purchasing an additional 62 shares in the last quarter. Finally, Trifecta Capital Advisors LLC lifted its holdings in Becton, Dickinson and Company by 59.0% in the 3rd quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 62 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the sale, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 6,906 shares of company stock valued at $1,265,855. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $198.96 on Friday. The firm has a market capitalization of $54.82 billion, a P/E ratio of 59.93, a PEG ratio of 13.41 and a beta of 0.21. The stock has a fifty day moving average price of $185.41 and a 200 day moving average price of $165.10. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $200.47. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The firm had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the business posted $3.68 earnings per share. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend was Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Wall Street Analyst Weigh In

Several research firms have issued reports on BDX. Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Zacks Research raised shares of Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. Piper Sandler upped their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Jefferies Financial Group reissued a “buy” rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Finally, TD Cowen raised their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $185.07.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.